Drug intelligence / Profile preview

FAST CEA-targeted CAR-T

Development stage: Unknown
Lead developer: Protheragen
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous, Intraperitoneal

Overview

FAST CEA-targeted CAR-T is a chimeric antigen receptor T-cell therapy designed to target carcinoembryonic antigen (CEA), which is highly expressed in many gastrointestinal tumors, particularly colorectal cancer. This therapy has been evaluated in clinical trials for patients with CEA-positive solid tumors, showing some efficacy in stabilizing disease and reducing tumor burden. The therapy works by engineering a patient's T cells to express a receptor that recognizes CEA, enabling them to target and kill CEA-expressing cancer cells.

Beyond the preview

Go deeper on FAST CEA-targeted CAR-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FAST CEA-targeted CAR-T.

Explore the full profile